THE GENERAL PHARMACEUTICAL COUNCIL AND ESTEVE SIGN AN AGREEMENT TO PROMOTE ADHERENCE IN CHRONIC AND POLYMEDICATED PATIENTS
This alliance will allow starting up the ADHIERETE Program to evaluate health care provided by community pharmacists.
General Pharmaceutical Council chairwoman Carmen Peña and ESTEVE director Antoni Esteve signed an agreement to start up the ADHIERETE Program, where adherence to treatment in chronic, polymedicated, noncompliant elderly patients will be evaluated.
This program will be developed in three Autonomous Communities and will focus on health care provided by community pharmacists to achieve better adherence to and better safety and effectiveness of medication. This will in turn improve the patient's quality of life and the sustainability of the Health System. For this purpose, a study including some 45 pharmacies and 225 patients will be started up in the coming months to evaluate the impact of the program in terms of cost-benefit and in terms of health.
The pharmacies participating in the program will develop a number of healthcare activities, including drug therapy follow-up, review of medical supplies, detection and resolution of drug-related problems (DRPs), etc. Also, utility tools such as customized dosing systems and mobile drug delivery systems will improve pharmacist-patient communication by way of notifications and warnings to the patient to ensure treatment compliance.
The decision to start up this program is based on the results of a pilot study performed in Azuaga (Extremadura) in 2010, where patient adherence improved from 41.2% to 70.6% after pharmacist interventions. The program is in line with the objectives of the Community Pharmacy Plan For The Future and meets the challenge of expanding the professional model to obtain critical mass, facilitate patient management, and contribute to the National Health System's efficiency. Also, this program has been selected by the European Commission to be part of the Partnership on Active and Healthy Ageing.
Health care efficiency
According to the WHO, 50% of patients with chronic diseases in developed countries fail to properly comply with their treatments as prescribed. Moreover, no adherence contributes to some 200,000 deaths in Europe every year and places a burden of 125 billion Euros for the healthcare system ―some 11.25 billion a year in Spain. These figures show the magnitude of the problem of nonadherence, a problem that appears to be efficiently addressed by pharmacy care-related services.
This action is part of the 12 objectives set by the General Council for 2013, and reflects the commitment of Pharmacy to patients and health services alike. It also highlights the pharmacist's role and the potential of the pharmacy network in health care.
This new agreement between ESTEVE and the General Council is yet another step forward in the Company's commitment to chronicity. Indeed, ESTEVE has built up a wealth of experience in terms of constant improvement and search for projects set to improve adherence to treatment and thus enhance people's quality of life, particularly in chronic and polymedicated patients. Also, research being ESTEVE's hallmark, a portfolio of highly innovating projects aims to provide responses to unmet medical needs.
You may follow ESTEVE at Twitter's link: twitter.com/esteve_news.
THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’
Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...read more
PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES
Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...read more
ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER
ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...read more